BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36167834)

  • 1. How Effective is the Use of Molecular Testing in Preoperative Decision Making for Management of Indeterminate Thyroid Nodules?
    Steinmetz D; Kim M; Choi JH; Yeager T; Samuel K; Khajoueinejad N; Buseck A; Imtiaz S; Fernandez-Ranvier G; Lee D; Owen R; Taye A
    World J Surg; 2022 Dec; 46(12):3043-3050. PubMed ID: 36167834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ThyroSeq
    Rivas AM; Nassar A; Zhang J; Casler JD; Chindris AM; Smallridge R; Bernet V
    Endocr Pract; 2018 Sep; 24(9):780-788. PubMed ID: 30084677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
    Witt RL
    Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeat Fine-Needle Aspiration With Molecular Analysis in Management of Indeterminate Thyroid Nodules.
    Papazian MR; Dublin JC; Patel KN; Oweity T; Jacobson AS; Brandler TC; Givi B
    Otolaryngol Head Neck Surg; 2023 Apr; 168(4):738-744. PubMed ID: 35412868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules.
    Scola WH; Linhares SM; Handelsman RS; Picado O; Khan ZF; Farrá JC; Lew JI
    J Surg Res; 2021 Dec; 268():209-213. PubMed ID: 34358733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ThyroSeq v2 Testing: Impact on Cytologic Diagnosis, Management, and Cost of Care in Patients with Thyroid Nodule.
    Fazeli SR; Zehr B; Amraei R; Toraldo G; Guan H; Kindelberger D; Lee S; Cerda S
    Thyroid; 2020 Oct; 30(10):1528-1534. PubMed ID: 32349630
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology.
    Valderrabano P; Khazai L; Leon ME; Thompson ZJ; Ma Z; Chung CH; Hallanger-Johnson JE; Otto KJ; Rogers KD; Centeno BA; McIver B
    Endocr Relat Cancer; 2017 Mar; 24(3):127-136. PubMed ID: 28104680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial.
    Livhits MJ; Zhu CY; Kuo EJ; Nguyen DT; Kim J; Tseng CH; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
    JAMA Oncol; 2021 Jan; 7(1):70-77. PubMed ID: 33300952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
    Hu TX; Nguyen DT; Patel M; Beckett K; Douek M; Masamed R; Rhyu J; Kim J; Tseng CH; Yeh MW; Livhits MJ
    Thyroid; 2022 Aug; 32(8):905-916. PubMed ID: 35611970
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid Cancer.
    Schumm MA; Shu ML; Hughes EG; Nikiforov YE; Nikiforova MN; Wald AI; Lechner MG; Tseng CH; Sajed DP; Wu JX; Yeh MW; Livhits MJ
    JAMA Otolaryngol Head Neck Surg; 2023 Aug; 149(8):735-742. PubMed ID: 37382944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3.
    Kim NE; Raghunathan RS; Hughes EG; Longstaff XR; Tseng CH; Li S; Cheung DS; Gofnung YA; Famini P; Wu JX; Yeh MW; Livhits MJ
    J Clin Endocrinol Metab; 2023 Aug; 108(9):e698-e703. PubMed ID: 36995878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
    Gortakowski M; Feghali K; Osakwe I
    Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular Testing for Indeterminate Thyroid Nodules: Association of Negative Predictive Value With Nodule Size.
    Barnes AB; Justice-Clark T; Li W; Randle RW
    Am Surg; 2022 Nov; 88(11):2745-2751. PubMed ID: 35723175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Expression Classifier vs Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules.
    Livhits MJ; Kuo EJ; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Zanocco KA; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2261-2268. PubMed ID: 29590358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
    Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
    Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
    Jug RC; Datto MB; Jiang XS
    Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative Results on Thyroid Molecular Testing Decrease Rates of Surgery for Indeterminate Thyroid Nodules.
    Jug R; Parajuli S; Ahmadi S; Jiang XS
    Endocr Pathol; 2019 Jun; 30(2):134-137. PubMed ID: 30825100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis.
    Borowczyk M; Szczepanek-Parulska E; Olejarz M; Więckowska B; Verburg FA; Dębicki S; Budny B; Janicka-Jedyńska M; Ziemnicka K; Ruchała M
    Endocr Pathol; 2019 Mar; 30(1):8-15. PubMed ID: 30591992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review.
    Hier J; Avior G; Pusztaszeri M; Krasner JR; Alyouha N; Forest VI; Hier MP; Mlynarek A; Richardson K; Sadeghi N; Tamilia M; Payne RJ
    J Otolaryngol Head Neck Surg; 2021 Apr; 50(1):29. PubMed ID: 33910629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
    Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
    JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.